The recent study revealed that the use of neoadjuvant combination chemotherapy may be safe and effective and could be therapeutically beneficial for patients with resectable pancreatic adenocarcinoma (PACT). The use of new combinations of chemotherapy in patients with pancreatic cancer have increased the survival rate, yet the prognosis of this disease remains poor, even for patients who present with early-stage disease. In this regard, the study reported the safety and efficacy of neoadjuvant combination chemotherapy in patients with resectable pancreatic adenocarcinoma.
Moreover, the neoadjuvant combination regimen provided additional therapeutic benefit compared to benefits achieved with adjuvant-only administration. For this study, a total of 88 patients (age between 18–75 years) with previously untreated pancreatic adenocarcinoma were recruited. They were divided into three groups…
